Edition:
United States

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

56.42EUR
6:29am EDT
Change (% chg)

€0.54 (+0.97%)
Prev Close
€55.88
Open
€55.96
Day's High
€56.44
Day's Low
€55.96
Volume
82,534
Avg. Vol
358,250
52-wk High
€58.80
52-wk Low
€33.51

Latest Key Developments (Source: Significant Developments)

Germany's Stada receives 58 euros/share offer from two private equity groups- ft
Tuesday, 14 Mar 2017 05:57pm EDT 

:Group made up of Advent International, Permira and one comprised of Bain Capital, Cinven each made formal 58 euros/share offers for Germany's Stada- FT.  Full Article

Stada Arzneimittel AG confirms takeover bid from Cinven Partners
Sunday, 12 Feb 2017 04:14pm EST 

Stada Arzneimittel AG : Stada Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid . Stada Arzneimittel - received two legally non-binding expressions of interest regarding bid for acquisition of up to 100 percent of the shares in co . Stada Arzneimittel - received non-binding expression of interest from cinven partners at an indicative takeover price of euro 56.00 per stada share . Stada Arzneimittel - it is not yet possible to foresee whether a takeover offer from cinven or the other potential bidder will indeed materialise. .Stada Arzneimittel - Stada is currently weighing up its options on how to react in the best interest of the company.  Full Article

Stada names new board member to oversee R&D
Monday, 23 Jan 2017 04:00am EST 

Stada : Says announces changes in the executive board of Stada . Says Barthold Piening to be responsible for production, research and development, biotechnology as well as quality assurance and control .Says new executive board remuneration system developed.  Full Article

New Stada CEO says not in a leadership dispute
Thursday, 4 Aug 2016 04:26am EDT 

Stada Arzneimittel AG's new CEO Matthias Wiedenfels : Says there is no dispute with previous CEO Retzlaff over leadership of company Further company coverage: [STAGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Stada says on the path to reconfigering supervisory board
Wednesday, 6 Jul 2016 06:20am EDT 

Stada : Stada Arzneimittel AG: important step on the path to reconfiguring the stada supervisory board . Says supervisory board to propose to annual general meeting on august 26, 2016 four candidates for election with a term of office of five years .Says structured process for selection of candidates successfully completed.  Full Article

Stada shareholder says company not acting in the interest of shareholders
Friday, 1 Jul 2016 09:28am EDT 

Stada shareholder DWS says : Not under the impression that Stada has been acting in the interest of Stada shareholders, would welcome improvement of corporate governance Further company coverage: [STAGn.DE] ((Frankfurt.newsroom@thomsonreuters.com; +49 7565 1272;)).  Full Article

Stada Arzneimittel AG says exec Wiedenfels to replace Retzlaff as CEO
Sunday, 5 Jun 2016 12:53pm EDT 

Stada Arzneimittel AG : Says change in leadership . Says Hartmut Retzlaff lays down office as chief executive officer due to medical reasons . Says executive board members Helmut Kraft, Matthias Wiedenfels jointly take over areas of responsibility overseen by the CEO .Says Matthias Wiedenfels initially appointed by supervisory board as CEO.  Full Article

Stada expects German generics business to show roughly same trends in Q2 as in Q1
Thursday, 12 May 2016 07:39am EDT 

Stada CFO on conference call with analysts: Stada says very confident of reaching target for 2016 adj net profit of at least 170 million eur . Stada says expects german generics business to show roughly same trends in q2 as in q1 Further company coverage: [STAGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

STADA Arzneimittel secures additional promissory note loans of total of EUR 350 mln
Tuesday, 26 Apr 2016 04:00am EDT 

STADA Arzneimittel AG:Has secured additional promissory note loans of a total of 350 million euros.With the new promissory note loans, STADA has refinanced promissory note loans in the amount of 188.0 million euros, which will expire in Dec. 2016.Promissory note loans, which are divided into four tranches and have terms of between five and seven years, have both fixed and variable interest rates.  Full Article

STADA Arzneimittel comments on FY 2016 outlook, to propose FY 2015 dividend
Wednesday, 23 Mar 2016 02:25am EDT 

STADA Arzneimittel AG:Proposes a dividend of 0.70 euros per share for FY 2015 (previous year: 0.66 euros/shr).For the outlook for FY 2016, anticipates slight growth in Group sales adjusted for currency and portfolio effects, adjusted EBITDA and adjusted net income.FY 2015 reported group sales 2,115.1 million euros.FY 2016 revenue estimate 2,194 million euros - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

Private equity firm Cinven in talks to buy chemicals firm CHRYSO

PARIS Private equity firm Cinven is in talks to buy CHRYSO, a French chemicals group with 2016 sales of 300 million euros ($324 million), from LBO France, the companies said on Friday.